Search results for "Progestin"

showing 10 items of 32 documents

The action of estrogens and progestogens in the young female breast

2018

Evidence from different sources sustains a pro-oncogenic role of hormones, estrogens and progestogens, on the breast. The issue is of interest for young women, who are exposed to the hormonal changes imposed by the ovarian cycle and, often, take hormones with contraceptive purposes. Experimental and clinical studies show that both estrogens and progesterone are involved in mammary development during puberty and lactation, the changes being observed across mammalian species, including humans. Estrogen receptors, and more particularly the alpha isoform, participate in molecular processes of stem cells differentiation and epithelial proliferation through paracrine actions implicating growth fa…

Adult0301 basic medicinemedicine.medical_specialtymedicine.drug_classEstrogen receptorBreast NeoplasmsContraceptives Oral HormonalYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansBreastAromataseAromatase inhibitorbiologybusiness.industryObstetrics and GynecologyEstrogensmedicine.disease030104 developmental biologyEndocrinologyPremenopauseReceptors EstrogenReproductive MedicineEstrogenSelective estrogen receptor modulator030220 oncology & carcinogenesisbiology.proteinFemaleProgestinsReceptors Progesteronebusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugHormoneEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

1994

Objective To determine the effectiveness of GnRH-agonist (GnRH-a) treatment in women with late onset congenital adrenal hyperplasia. Design Prospective assessment of GnRH-a treatment in six women with documented late-on-set congenital adrenal hyperplasia who were not preselected. Comparisons were made to previous responses in the same patients receiving dexamethasone. Eight age- and weight-matched ovulatory women served as controls. Setting Academic medical center. Intervention Baseline blood determinations before and after IV ACTH, before and after 6months of GnRH-a treatment. Estrogen and progestin replacement was begun in all women after the 3rd month of treatment. Main Outcome Measures …

Adultendocrine systemmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classOvaryDexamethasoneInternal medicineEndocrine GlandsmedicineHydroxyprogesteronesHumansCongenital adrenal hyperplasiaProspective StudiesAge of OnsethirsutismDexamethasoneTriptorelin PamoatebiologyAdrenal Hyperplasia Congenitalbusiness.industry17-alpha-HydroxyprogesteroneOvary21-HydroxylaseObstetrics and Gynecologymedicine.diseaseAndrogenmedicine.anatomical_structureEndocrinologyReproductive MedicineEstrogenbiology.proteinAndrogensFemalebusinessProgestinhormones hormone substitutes and hormone antagonistsGonadotropinsmedicine.drugFertility and sterility
researchProduct

Progestogens to prevent preterm birth in twin pregnancies:an individual participant data meta-analysis of randomized trials

2012

Abstract Background Preterm birth is the principal factor contributing to adverse outcomes in multiple pregnancies. Randomized controlled trials of progestogens to prevent preterm birth in twin pregnancies have shown no clear benefits. However, individual studies have not had sufficient power to evaluate potential benefits in women at particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to determine adverse effects for rare outcomes such as intrauterine death. Methods/design We propose an individual participant data meta-analysis of high quality randomized, double-blind, placebo-controlled trials of progestogen treatment in women with …

Adultmedicine.medical_specialtyReproductive medicine/dk/atira/pure/subjectarea/asjc/2700/2729lcsh:Gynecology and obstetricslaw.inventionStudy ProtocolClinical ProtocolsRandomized controlled trialPregnancylawObstetrics and GynaecologymedicineHumansAdverse effectTwin Pregnancylcsh:RG1-991Randomized Controlled Trials as TopicPregnancyModels StatisticalObstetricsbusiness.industryIndividual participant dataInfant NewbornPregnancy OutcomeObstetrics and Gynecologymedicine.diseasePregnancy ComplicationsPremature birthMeta-analysisPregnancy TwinPremature BirthFemaleProgestinsbusiness
researchProduct

The effect of hormonal status on the expression of estrogen and progesterone receptor in vaginal wall and periurethral tissue in urogynecological pat…

2009

Abstract Objective Our objective was to study the expression of estrogen receptor (ER) isoforms ER alpha (α) and ER beta (β) and of progesterone receptor (PR) in the vaginal wall and in periurethral tissue of women who underwent urogynecological surgical treatment with reference to estrogen status. Study design The study included 89 patients undergoing vaginal surgery for urogynecological conditions. Patients’ history and clinical data including estrogen status and body mass index (BMI) were evaluated. Biopsies from the vaginal wall and from periurethral tissue were obtained during surgery. The expression of ER α and β and of PR in vaginal wall and periurethral tissue was measured by RT-PCR…

Adultmedicine.medical_specialtymedicine.drug_classReceptor expressionEstrogen receptorUrethraInternal medicineProgesterone receptormedicineHumansEstrogen receptor betaAgedAged 80 and overReverse Transcriptase Polymerase Chain Reactionbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle AgedEndocrinologymedicine.anatomical_structureReceptors EstrogenReproductive MedicineEstrogenVaginaVaginaFemaleReceptors ProgesteronebusinessProgestinEstrogen receptor alphaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

2016

The present study investigated the combination of levonorgestrel-releasing intrauterine device (LNG-IUD) insertion and palliative radiotherapy (RT) as a potential approach for treating frail, elderly endometrial cancer (EC) patients considered unfit for curative oncological treatments. The inclusion criteria were an age of ≥65 years, pathological confirmation of a uterine neoplasm, a Charlson comorbidity index (CCI) value of ≥4 and the presence of vaginal bleeding. Patients underwent intrauterine insertion of an LNG-IUD, and thereafter, received a total dose of 30 Gy at 3 Gy per fraction, over 10 days. The clinical target volume (CTV) was defined as the uterus and disease-involved tissues i…

Cancer Researchmedicine.medical_specialtymedicine.drug_classUterusIntrauterine deviceelderlyuterine cancer03 medical and health sciences0302 clinical medicineUterine cancermedicineVaginal bleedingUterine NeoplasmSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAprogestin-releasing intrauterine device030219 obstetrics & reproductive medicinebusiness.industryEndometrial cancerCancerArticlesmedicine.diseaseSurgeryElderly; Palliative radiotherapy; Progestin-releasing intrauterine device; Uterine cancer; Oncology; Cancer Researchmedicine.anatomical_structureOncology030220 oncology & carcinogenesispalliative radiotherapymedicine.symptombusinessProgestinOncology letters
researchProduct

Effectiveness of progestogens to improve perinatal outcome in twin pregnancies : an individual participant data meta-analysis

2015

Background In twin pregnancies, the rates of adverse perinatal outcome and subsequent long-term morbidity are substantial, and mainly result from preterm birth (PTB). Objectives To assess the effectiveness of progestogen treatment in the prevention of neonatal morbidity or PTB in twin pregnancies using individual participant data meta-analysis (IPDMA). Search strategy We searched international scientific databases, trial registration websites, and references of identified articles. Selection criteria Randomised clinical trials (RCTs) of 17–hydroxyprogesterone caproate (17Pc) or vaginally administered natural progesterone, compared with placebo or no treatment. Data collection and analysis I…

Cervical pessaryAdultmedicine.medical_specialtymedicine.medical_treatmentPerinatal DeathDiseasesCervix UteriInfant Newborn DiseasesEnterocolitis NecrotizingPregnancy17 alpha-Hydroxyprogesterone CaproatemedicineHydroxyprogesteronesHumansTwin PregnancyProgesteroneBronchopulmonary DysplasiaCerebral HemorrhagePregnancyRespiratory Distress SyndromeRespiratory Distress Syndrome NewbornProgestogenIntravaginalObstetricsbusiness.industryEnterocolitisInfant NewbornObstetrics and GynecologyInfantTwinmedicine.diseaseNewbornCervical Length MeasurementClinical trialAdministration IntravaginalTreatment OutcomePremature birthCervical Length MeasurementRelative riskAdministrationPregnancy TwinPremature BirthFemaleProgestinsbusinessNecrotizing
researchProduct

Dydrogesterone use during pregnancy: Overview of birth defects reported since 1977

2009

Between 1977 and 2005, 28 cases of potential links between maternal dydrogesterone use during pregnancy and congenital birth defects were reported. The types of defects were very diverse, with no evidence of a pattern of abnormalities. The data do not provide evidence for congenital malformations associated with dydrogesterone use.

Gynecologymedicine.medical_specialtyPregnancyProgestogenObstetricsbusiness.industrymedicine.medical_treatmentAbnormalities Drug-InducedObstetrics and GynecologyCongenital malformationsDydrogesteronemedicine.diseaseMaternal ExposurePregnancyPediatrics Perinatology and Child HealthDydrogesteronemedicineAdverse Drug Reaction Reporting SystemsHumansGestationFemaleProgestinsbusinessmedicine.drugEarly Human Development
researchProduct

Hepatic lipase and lipoprotein lipase are affected by combined estrogen+progestin hormone therapy

2004

Hepatic lipase lipoprotein lipase estrogen progestin therapy
researchProduct

Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor

1990

Abstract Some progestogens widely used in oral contraceptives are characterized at the level of high-affinity receptor binding as well as binding to sex hormone-binding globulin and corticosteroid-binding globulin. With regard to binding to sex hormone-binding globulin, gestodene, levonorgestrel, and to a lesser extent 3-ketodesogestrel (which is only formed from the prodrug desogestrel in the body), show a behavior that is manifested in the relatively high affinity to sex hormone-binding globulin, whereas desogestrel and norgestimate do not display any measurable affinity for this specific steroid-binding serum protein. Furthermore, levonorgestrel and gestodene dissociate very much more sl…

MaleCytoplasmmedicine.medical_specialtyNorpregnenesmedicine.medical_treatmentReceptors Cell SurfaceLevonorgestrelCytoplasmic receptorGestodeneBinding CompetitiveContraceptives Oral HormonalSex hormone-binding globulinPregnancyDesogestrelSex Hormone-Binding GlobulinInternal medicineNorgestrelmedicineAnimalsHumansLevonorgestrelProgesteroneTranscortinDesogestrelProgesterone CongenersProgestogenbiologybusiness.industryNorgestrelUterusObstetrics and GynecologyRats Inbred StrainsBlood ProteinsNorgestimateRatsKineticsEndocrinologybiology.proteinFemaleProgestinsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugAmerican Journal of Obstetrics and Gynecology
researchProduct